Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps delivering the hard truth.

Whatever the consensus opinion may be, our team at StockStory cuts through the noise by conducting independent analysis to determine a company’s long-term prospects. That said, here are three stocks where the skepticism is well-placed and some better opportunities to consider.

Trinity (TRN)

Consensus Price Target: $35 (-4.8% implied return)

Operating under the trade name TrinityRail, Trinity (NYSE: TRN) is a provider of railcar products and services in North America.

Why Do We Think Twice About TRN?

1. Backlog has dropped by 25.8% on average over the past two years, suggesting it’s losing orders as competition picks up
2. Demand will likely be weak over the next 12 months as Wall Street expects flat revenue
3. Free cash flow margin dropped by 22.9 percentage points over the last five years, implying the company became more capital intensive as competition picked up

Trinity’s stock price of $36.78 implies a valuation ratio of 14.9x forward P/E. If you’re considering TRN for your portfolio, see our FREE research report to learn more.

CVS Health (CVS)

Consensus Price Target: $111.92 (4.7% implied return)

With over 9,000 retail pharmacy locations serving as neighborhood health destinations across America, CVS Health (NYSE: CVS) operates retail pharmacies, provides pharmacy benefit management services, and offers health insurance through its Aetna subsidiary.

Why Does CVS Fall Short?

1. Large revenue base makes it harder to increase sales quickly, and its annual revenue growth of 6.3% over the last two years was below our standards for the healthcare sector
2. Demand is forecasted to shrink as its estimated sales for the next 12 months are flat
3. Performance over the past five years shows its incremental sales were much less profitable, as its earnings per share fell by 1.5% annually

CVS Health is trading at $106.89 per share, or 14.1x forward P/E. Check out our free in-depth research report to learn more about why CVS doesn’t pass our bar.

Old Republic International (ORI)

Consensus Price Target: $41.50 (0.4% implied return)

Founded during the Roaring Twenties in 1923 and weathering nearly a century of economic cycles, Old Republic International (NYSE: ORI) is a diversified insurance holding company that provides property, liability, title, and mortgage guaranty insurance through its various subsidiaries.

Why Should You Sell ORI?

1. Annual revenue growth of 1.6% over the last five years was below our standards for the insurance sector
2. Sluggish 2.9% annualized growth in net premiums earned over the last five years indicates the firm trailed its insurance peers
3. Incremental sales over the last two years were less profitable as its 2.1% annual earnings per share growth lagged its revenue gains

At $41.35 per share, Old Republic International trades at 1.6x forward P/B. To fully understand why you should be careful with ORI, check out our full research report (it’s free).

Stocks We Like More

WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don’t just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.

But our AI platform says the party isn’t over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+214% between June 2020 and June 2025). Find your next big winner with StockStory today.